tiprankstipranks
Trending News
More News >
Sofwave Medical Ltd. (IL:SOFW)
:SOFW
Israel Market

Sofwave (SOFW) AI Stock Analysis

Compare
3 Followers

Top Page

IL:SOFW

Sofwave

(SOFW)

Select Model
Select Model
Select Model
Neutral 64 (OpenAI - 5.2)
Rating:64Neutral
Price Target:
3,478.00
▲(24.21% Upside)
The score is primarily supported by strong financial momentum (rapid revenue growth, strong gross margins, improving cash flow, and low leverage) and constructive technical trend signals. It is meaningfully tempered by very expensive valuation (P/E 577.38) and ongoing profitability/ROE weakness, with RSI suggesting the stock may be overextended near-term.
Positive Factors
Rapid revenue growth
Sustained TTM revenue growth of ~82.5% shows durable market adoption of Sofwave's ultrasound platform. Over a multi-month horizon this supports expanding clinic penetration, a growing installed base, and operating leverage potential that can fund R&D, training and commercial scale.
High gross margins
A ~76% gross margin reflects strong product economics for devices and consumables. Structurally high gross margins provide a lasting cushion to absorb SG&A, support investment in clinical evidence and training, and make sustainable operating profitability achievable as volume scales.
Low leverage with improving cash generation
Very low debt-to-equity and a 326% TTM free cash flow improvement indicate a resilient balance sheet and improving cash conversion. This structural strength increases financial flexibility for capex, partnerships or M&A and reduces refinancing risk during multi-month cycles.
Negative Factors
Negative net profitability and ROE
Despite strong revenue and gross margins, Sofwave reports a negative net margin and negative ROE. Persisting unprofitability hampers long-term shareholder value creation and implies the company must deliver sustained operating leverage or cut costs to convert top-line strength into durable profits.
Limited organizational scale
A headcount of 126 suggests constrained commercial, clinical and support capacity versus larger peers. Limited scale can raise per-unit SG&A, slow geographic roll-out and make margin improvement heavily dependent on rapid personnel and distribution scaling over the coming months.
Concentrated revenue model reliant on device sales
Reliance on capital equipment and consumable sales creates lumpy, cycle-driven revenue and limits predictability. Unless recurring service/maintenance or consumable attachment rates grow materially, revenue and margin stability will remain sensitive to replacement cycles and procedure demand.

Sofwave (SOFW) vs. iShares MSCI Israel ETF (EIS)

Sofwave Business Overview & Revenue Model

Company DescriptionSofwave Medical Ltd. develops an ultrasound technology for treating fine lines and wrinkles in Israel and internationally. It offers non-invasive skin treatment aesthetic medical devices to physicians. The company was incorporated in 2015 and is based in Yokne'am Illit, Israel.
How the Company Makes MoneySofwave generates revenue primarily through the sale of its medical devices and related consumables to healthcare providers, including dermatologists and cosmetic surgeons. The company operates a direct sales model, often providing training and support to practitioners to ensure the effective use of their devices. Additionally, Sofwave may generate recurring revenue from service agreements and maintenance for their equipment. Partnerships with healthcare institutions and participation in industry conferences also enhance their market presence and can lead to increased sales opportunities, contributing to overall earnings.

Sofwave Financial Statement Overview

Summary
Sofwave shows positive revenue growth and a strong gross profit margin, but struggles with profitability and cash flow stability. The low debt profile is a positive, but negative net profit margins and declining free cash flow growth are concerning.
Income Statement
Sofwave has shown a positive revenue growth rate of 10.05% in the TTM, indicating a growing market presence. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin remains strong at 76.25%, suggesting efficient production processes, but the overall profitability is hindered by high operating expenses.
Balance Sheet
The balance sheet reflects a stable financial position with a low debt-to-equity ratio of 0.06, indicating low leverage and reduced financial risk. However, the return on equity is negative, highlighting challenges in generating returns for shareholders. The equity ratio is healthy, suggesting a solid capital structure.
Cash Flow
The cash flow statement shows a concerning decline in free cash flow growth, with a significant negative growth rate of -197.34% in the TTM. Despite this, the company maintains a positive free cash flow to net income ratio, indicating some ability to convert profits into cash. The operating cash flow to net income ratio is negative, reflecting challenges in cash generation from operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue126.83M59.65M50.31M35.63M21.84M4.29M
Gross Profit94.90M45.34M37.48M26.33M16.24M2.63M
EBITDA8.98M-2.19M-6.61M-17.55M-6.43M-11.32M
Net Income3.00M-4.55M-8.28M-19.53M-6.83M-11.69M
Balance Sheet
Total Assets155.15M43.03M43.54M46.08M60.77M4.82M
Cash, Cash Equivalents and Short-Term Investments87.62M21.62M24.42M32.01M46.22M2.64M
Total Debt4.49M1.40M1.33M1.92M2.37M78.00K
Total Liabilities62.60M18.50M17.19M13.74M14.07M3.29M
Stockholders Equity92.55M24.53M26.34M32.34M46.70M1.53M
Cash Flow
Free Cash Flow11.09M-2.67M-6.71M-11.14M-2.92M-5.07M
Operating Cash Flow11.73M-2.40M-6.31M-10.69M-2.10M-4.80M
Investing Cash Flow-857.35K254.00K409.00K-260.00K-982.00K-263.00K
Financing Cash Flow-572.13K-620.00K-1.72M-1.35M46.64M1.99M

Sofwave Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2800.00
Price Trends
50DMA
2911.46
Positive
100DMA
2860.54
Positive
200DMA
2427.51
Positive
Market Momentum
MACD
119.30
Negative
RSI
75.90
Negative
STOCH
90.76
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:SOFW, the sentiment is Positive. The current price of 2800 is below the 20-day moving average (MA) of 2928.55, below the 50-day MA of 2911.46, and above the 200-day MA of 2427.51, indicating a bullish trend. The MACD of 119.30 indicates Negative momentum. The RSI at 75.90 is Negative, neither overbought nor oversold. The STOCH value of 90.76 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IL:SOFW.

Sofwave Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
1.51B64.6710.95%21.13%251.25%
64
Neutral
1.27B654.5029.55%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IL:SOFW
Sofwave
3,677.00
2,145.00
140.01%
IL:BWAY
Brainsway
3,799.00
1,972.00
107.94%
IL:ILX
Ilex Medical
6,660.00
-510.84
-7.12%
IL:ALMD
Allmed Solution
33.00
0.90
2.80%
IL:EPIT
Epitomee Med
703.80
-233.50
-24.91%
IL:PULS
Pulsenmore
1,865.00
-1,286.81
-40.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 08, 2026